YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

Initial deployment is expected to focus on corporate partners, with healthcare expansion planned after successful implementation.

Rhea-AI Summary

YD Bio (Nasdaq: YDES) announced a collaboration with affiliate EG BioMed and digital health provider JoiiUp to integrate cancer-risk assessment into JoiiSports.

The jointly developed AI Cancer Risk Assessment uses self-reported health information to generate risk reports and lifestyle recommendations. It was developed with three Taipei Medical University-affiliated hospitals and validated using over 1,200 clinical records. Initial deployment is expected to focus on JoiiUp’s existing corporate partner network. The companies plan to expand to healthcare institutions following successful corporate implementation.

The assessment is a risk-stratification and health guidance tool, not a diagnostic or screening test. Its output does not represent the probability of developing cancer, and it cannot replace professional medical evaluation or recommended cancer screening.

News Explained

YD Bio says its January 2026 MOU to merge with EG BioMed is advancing, with closing anticipated in 2026 subject to customary conditions, regulatory approvals and finalizing definitive agreements; the release gives no merger consideration.

Key Figures

Clinical records: over 1,200 clinical records Affiliated hospitals: three hospitals Corporate reach: over 400 companies +1 more

Clinical records

over 1,200 clinical records

Assessment validation

Affiliated hospitals

three hospitals

Development of the Assessment

Corporate reach

over 400 companies

JoiiUp workplace wellness programs

Cancer types

ten cancer types

Assessment coverage

Historical Context

1 past event · Latest: Oct 06

1 event

1. Oct 06

   AI assessment launch

   24h Move

   -13.5%

   YD Bio and EG BioMed launched the ten-cancer risk assessment before its JoiiSports integration.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dna methylation, single sign-on (sso), risk-stratification, laboratory-developed test

4 terms

dna methylation medical

"a biotechnology company advancing DNA methylation-based cancer detection"

A chemical tag added to DNA that acts like a sticky note on a recipe, changing whether a gene is read without altering the underlying genetic code. For investors, DNA methylation matters because these tags can serve as measurable biomarkers for disease diagnosis, risk prediction, and treatment response, and they can be targets for drugs or diagnostic tests—factors that influence clinical value, regulatory approval, and market potential.

single sign-on (sso) technical

"By leveraging Single Sign-On (SSO), users can seamlessly access the Assessment"

Single sign-on (SSO) is a login system that lets a user access multiple online services with one set of credentials, like using a single key to open several doors. For investors, SSO matters because it can lower a company’s support costs, improve employee productivity and customer convenience, but it also concentrates access risk—a single compromise can affect many systems and therefore has potential operational and reputational impact.

risk-stratification medical

"The Assessment is a cancer risk-stratification and health guidance tool."

The process of evaluating and grouping people, securities, counterparties, or situations by their likelihood and potential severity of an adverse outcome so that different levels of attention or action can be applied. It uses measurable factors or scores and pre-set thresholds to classify items into categories (for example: low, medium, high) and is inherently probabilistic — classifications indicate relative risk, not certainty, and can change as new information becomes available.

laboratory-developed test regulatory

"under a laboratory-developed test strategy"

A laboratory-developed test is a diagnostic test that a single clinical laboratory designs, builds and uses in its own facility rather than buying from an outside manufacturer; think of it as a custom recipe made and run in-house for diagnosing disease. Investors care because these tests can be quicker to bring to market and create a revenue stream for labs, but they also carry regulatory and quality-risk differences that can affect demand, reimbursement and legal exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly developed by YD Bio and EG BioMed, into JoiiUp’s JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions.

Key Collaboration Highlights

• Clinically Validated Data: The Assessment was developed in collaboration with three Taipei Medical University (TMU) affiliated hospitals and validated using over 1,200 clinical records.
• Broad Immediate Reach: JoiiUp brings over 12 years of workplace health promotion experience, actively supporting the employee wellness programs of over 400 companies.
• Non-Invasive Profiling: The tool utilizes an online health questionnaire and proprietary AI models mapped against medical literature to analyze demographic data, lifestyle habits, and family history across ten cancer types—requiring no blood draws or imaging.
• Actionable Digital Integration: By leveraging Single Sign-On (SSO), users can seamlessly access the Assessment directly within the JoiiSports app to generate personalized risk reports and targeted lifestyle recommendations.
  
  

Strategic Market Integration

The integration will connect the Assessment with JoiiUp’s existing exercise, nutrition, and sleep management ecosystem. Initial deployment is expected to focus on JoiiUp’s existing corporate partner network, enabling employers to seamlessly add targeted cancer risk analysis to their employee health benefits. Following successful corporate implementation, the companies plan to expand the offering to healthcare institutions as a supplementary tool for patient education and consultation.

Management Perspectives

“A key to cancer prevention is understanding risk early and taking timely action,” said Dr. Ethan Shen, Chairman and CEO of YD Bio. “This Assessment is the first step in building a comprehensive cancer management pathway spanning risk assessment, early detection, and precision medicine. Through JoiiUp, we are bringing personalized risk analysis directly into everyday health management and supporting vital follow-up discussions with healthcare professionals.”

Dr. Ruo-Kai Lin, Professor at TMU and Chief of R&D at EG BioMed, noted: “Through questionnaires and personalized analysis, we hope to help users understand their risks and inform discussions with healthcare professionals. Partnering with JoiiUp makes this clinically validated information vastly more accessible.”

Important Regulatory Disclosure

The Assessment is a cancer risk-stratification and health guidance tool. It uses statistical and artificial intelligence methods applied to health information self-reported by the user. Its output does not represent the probability of developing cancer. It does not diagnose cancer and is not intended for cancer diagnosis, screening, early detection, disease prediction, or treatment decision-making; it cannot replace professional medical evaluation, diagnostic testing, or consultation with a qualified healthcare provider, and does not replace recommended cancer screening.

About JoiiUp

JoiiUp delivers smart health management and digital health services. Its JoiiSports app combines wearable devices, exercise and nutrition management, and AI health applications to build healthy lifestyles. The JoiiCare platform provides wellness activities and health management tools for over 400 corporate clients. For more information, visit www.joiiup.com.

About EG BioMed

EG BioMed is a biotechnology and clinical services company focused on advancing early cancer detection and diagnostic solutions. YD Bio entered into a Memorandum of Understanding to merge with EG BioMed in January 2026 and is advancing the transaction, which is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.

About YD Bio Limited

YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans, objectives and expectations for its business, strategy and operations; and the planned partnership with EG BioMed and JoiUpp, along with the associated integration of the Assessment into the JoiiSports app, the implementation approach, the anticipated commercial and strategic benefits of the partnership and related future expansion plans. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “intend,” “seek,” “believe,” “designed to,” “expects,” “anticipates,” “plans,” “may,” “could,” “hope,” “will” and other similar expressions. Actual results may differ materially from those expressed or implied due to a variety of factors, including system integration and implementation challenges; corporate client requirements; consumer demand and market acceptance; competition; regulatory and labeling requirements in Taiwan and other jurisdictions; currency exchange rates; geopolitical tensions and macroeconomic conditions; and other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission. The Company cautions investors not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statement, except as required by law, and encourages investors to review the risk factors in its Annual Report on Form 20-F and other SEC filings.

For investor and media inquiries, please contact:

YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is YD Bio’s collaboration with EG BioMed and JoiiUp?

The collaboration integrates an AI Cancer Risk Assessment, jointly developed by YD Bio and EG BioMed, into JoiiUp’s JoiiSports app. Initial deployment is expected to focus on JoiiUp’s existing corporate partner network, followed by planned expansion to healthcare institutions after successful corporate implementation.

Can YD Bio’s AI Cancer Risk Assessment diagnose or screen for cancer?

No. The assessment provides risk stratification and health guidance, not cancer diagnosis or screening. Its output does not represent the probability of developing cancer. It is not intended for early detection, disease prediction or treatment decisions, and does not replace professional medical evaluation or recommended cancer screening.